A NOVEL IMMUNE AGENT TARGETING PVR

{NTX-1088|This therapeutic agent represents the significant strategy for treating multiple diseases. It uniquely binds to CD155, a cellular protein involved in cell-cell adhesion and cancer spread. Preclinical data demonstrate that NTX-1088 can efficiently reduce this interaction, possibly causin